12:00 AM
 | 
Oct 04, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

KAI-4169: Phase Ib started

Kai began a double-blind, placebo-controlled, dose-escalation, crossover, Australian Phase Ib trial to evaluate single-ascending doses of IV KAI-4169...

Read the full 69 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >